GbS Global Biopharma ("GbS"), the wholly-owned Canadian subsidiary of GB Sciences, Inc. (OTCQB:GBLX), is a plant-inspired research and biopharma drug development company. Our goal is to create patented formulations of plant-inspired, optimized therapeutic mixtures (OTM) for the prescription drug market to treat a variety of conditions. The 'plant-inspired' active ingredients in our OTM are synthetic homologues identical to the original plant compounds, but produced synthetically under cGMP manufacturing controls. GbS' novel drug discovery platform has yielded 5 issued US and 3 issued international patents, as well as 19 US and 40 international patent-pending applications. In our drug development pipeline, GbS has five preclinical stage programs, and our lead Parkinson’s disease therapeutic program is being prepared for a First-in-Man clinical trial. In addition to Parkinson's disease, Gb is developing therapeutics for chronic pain, COVID-related cytokine release syndrome (CRS), Mast Cell Activation Syndrome (MCAS), anxiety, depression, and heart failure. GbS' productive research and development network includes nine universities, several hospitals, and Contract Research Organizations.